Supplementary Materials

The PDF file includes:

  • Fig. S1. Flow cytometry analysis of serpinB13 expression in mouse pancreatic epithelium during embryonic development.
  • Fig. S2. Quantitative analysis of Ngn3+ cells after inhibition of serpinB13 in mouse embryonic pancreas explants cultured in vitro.
  • Fig. S3. Quantitative analysis of CK19+ cells after inhibition of serpinB13 in mouse embryonic pancreas explants cultured in vitro.
  • Fig. S4. Western blot analysis of Ngn3 expression in vivo.
  • Fig. S5. Expression of serpinB13 and the impact of binding to distinct mAbs on the number of Ngn3+ pancreatic endocrine progenitor cells at birth.
  • Fig. S6. Impact of inhibition of serpinB13 on generation of glucagon-positive cells.
  • Fig. S7. Genetic tracing of Ngn3+ cells in the pancreas of healthy and diabetic adult mice treated with anti-serpinB13 mAb.
  • Fig. S8. Examination of the extracellular domain of Notch1 receptor.
  • Fig. S9. Impact of CatL on the number of Ngn3+ cells.
  • Fig. S10. Examination of the intracellular domain of the Notch1 receptor.
  • Fig. S11. Analysis of NOTCH1 gene expression.
  • Fig. S12. The pancreas and body weight in mice with exposure to anti-serpinB13 mAb during pregnancy and embryonic life.
  • Fig. S13. The severity of diabetes in adult mice after exposure to anti-serpinB13 mAb during embryonic life.
  • Fig. S14. The antigen specificity of anti-serpin human Abs.
  • Fig. S15. The dose-dependent control of CatL activity by recombinant human serpinB13 and the effect of anti-serpinB13 Ab on substrate cleavage.
  • Fig. S16. A model of the spatial relationship between serpinB13, CatL, and Ab response and its influence on progression to T1D.
  • Legends for data files S1 and S2

[Download PDF]

Other Supplementary Material for this manuscript includes the following: